MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

A new study adds to evidence to suggest the main ingredient in Novo Nordisk’s injectable drug for type 2 diabetes may ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Early treatment for chronic kidney disease often gets overlooked during routine clinical care. In fact, as many as one-third of patients with kidney failure have no record of health care treatment for ...

As a diabetes medication, GLP-1s are able to treat insulin resistance, something that many people with PCOS deal with. “It’s ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely comprehensive and reliable manner.

The rise of GLP-1s, which were initially approved for diabetes management and later for obesity treatment, underscores this ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...